Dmitriy Vladimirovich Goryachev

Dmitriy Vladimirovich Goryachev

Auto-generated profile, based on publicly available information

Dmitriy Vladimirovich Goryachev

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
ASA. P. Solovyova
A. P. Solovyova
DGD. V. Goryachev
D. V. Goryachev
VAV. V. Arkhipov
V. V. Arkhipov

22 September 2019 in Химико-фармацевтический журнал
Verified
Journal Article
Closed access
PDF file
НУНаталия Евгеньевна Уварова
Наталия Евгеньевна Уварова
NENatalia Eremenko
Natalia Eremenko
GRGalina Ramenskaya
Galina Ramenskaya
ДГДмитрий Владимирович Горячев
Дмитрий Владимирович Горячев
VSValery Smirnov
Valery Smirnov
Рассмотрены требования FDA к валидации биоаналитических методик, опубликованные в новом руководстве 2018 г., необходимые для подтверждения их надежности для определения концентрации анализируемого вещества. Кратко описана история регулирования валидации биоаналитических методик. Представлен обзор ключевых изменений и дополнений руководства FDA по валидации биоаналитических методик, которые включают в себя объединение требований к валидации хроматографических методик и методик связывания лиганда, указание на валидацию биомаркеров, выделение раздела, посвященного новым технологиям (например, методу сухой капли крови), введение концепции соответствия поставленным целям. Проведено сравнение требований к валидационным параметрам хроматографических методик руководства FDA и требований ЕАЭС. Несмотря на некоторые отличия, как в количестве параметров, так и в критериях их приемлемости, требования нового руководства FDA в целом согласуются с документом ЕАЭС.

19 June 2024 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Closed access
OSO. V. Shreder
O. V. Shreder
DGD. V. Goryachev
D. V. Goryachev
VMV. A. Merkulov
V. A. Merkulov
INTRODUCTION. A well-planned design of a clinical trial (CT) ensures valid results in assessing the efficacy and safety of medicines for human use. However, at present, there are no clear criteria for selecting the basic elements underlying the development of a CT design. This lack of selection criteria primarily concerns planning research hypotheses, calculating the expected therapeutic effect, statistical significance level, and study power, and selecting statistical models for sample size calculation.AIM. The authors aimed to systematise and harmonise the technical requirements for sample size determination in designing CTs.DISCUSSION. First, this article describes the basic requirements for and methodological approaches to designing CTs to assess the efficacy of medicines and to confirm their safety. Next, the article presents the basic principles for calculating the sample size to ensure the required CT power. Finally, the article covers the mathematical models describing the null and alternative hypotheses used in the development of basic statistical designs for efficacy and safety studies. A general requirement for the quality of a study sample is to ensure its representativeness, that is, its compliance with the target CT population. The selection of a mathematical (probabilistic) model to formulate research hypotheses and calculate study samples representative of the target population is based on general data from systematic reviews of previous studies on the therapeutic effects of the study product and the specific characteristics of the target population. In addition, model selection relies on the classification of the study product. Sample size calculation requires defining and justifying certain criteria at the stage of CT design and statistical model development, in line with the general requirements for representativeness. Software for calculating the statistical power and required sample size facilitates routine CT planning.CONCLUSIONS. The sample size determination requires more than the application of basic statistical models. Given the multitude of CT designs and methodological approaches to CT planning, treatment regimens, and data collection and analysis, it is necessary to consider the statistical design of each CT on a case-by-case basis. This consideration should include assessments of individual cases, survival analysis methods, relative risks, diagnostic tests, and adaptive and other infrequent CT designs. The above highlights the need to develop additional guidelines and information resources that would explain and demonstrate the use of probabilistic statistics. The resulting national standards should be harmonised with international standards.

3 December 2019 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
NGN. Engalycheva G
N. Engalycheva G
SDSyubaev R. D
Syubaev R. D
DGD. V. Goryachev
D. V. Goryachev
РСР. Д. Сюбаев
Р. Д. Сюбаев
Стандарты качества доклинических фармакологических исследований

7 September 2022 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
OSO. V. Shreder
O. V. Shreder
NBN. D. Bunyatyan
N. D. Bunyatyan
DGD. V. Goryachev
D. V. Goryachev
RSR. D. Subaev
R. D. Subaev
GEG. N. Engalycheva
G. N. Engalycheva
VKV. V. Kosenko
V. V. Kosenko
Generally, preclinical studies of medicines conducted in accordance with national and international regulatory recommendations allow minimising the risks of detecting serious adverse events in patients at the stage of clinical trials. Nevertheless, current analytical trends motivate the development of new prognostic approaches aimed at improving the reliability and accuracy of safety assessments.The aim of this study was to develop and test methodological approaches to comprehensive preclinical assessment of the key risk factors associated with the use of medicinal products in humans and to mathematical prediction of the corresponding benefits and risks.Materials and methods: the study combined information analysis and statistics; it used consolidated preclinical data on the protective properties of fabomotizole and national and international regulatory documents describing the principles and methods of evidence-based medicine, in particular, Bayesian statistics and prognostic research methods.Results: The article presents mathematical approaches developed to confirm the statistical reliability and prognostic significance of the results of preclinical assessment of the safety of medicines, based on Bayesian statistics, in particular, the concepts of weight of evidence (WoE), information value (IV), and normalised density (ND). Depending on the volume of the evaluated data, the WoE can be used to determine the weight of evidence of single variables, as well as entire groups of variables from individual tests or whole test panels, considered in the studies of general toxic effects, reproductive toxicity, genotoxicity and other studies characterising the condition of vital organs when evaluating the safety of medicines.Conclusions: The developed methodology allows evaluating the entire volume of information obtained in preclinical studies of medicinal products. The criteria in the form of WoE and IV in preclinical safety assessment of medicines can be used to estimate the benefits and risks of using medicines, including the products developed specifically for children and pregnant women.

16 June 2019 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
EPE. V. Petraneva
E. V. Petraneva
IPI. A. Proskurina
I. A. Proskurina
DGD. V. Goryachev
D. V. Goryachev
EKE. L. Kovaleva
E. L. Kovaleva
The need to strengthen the post-approval regulation of biological products stems from their increasing role in the treatment of serious human diseases. Until recently, there were open questions on the classification of changes and supporting data necessary to confirm the comparability of a biological medicinal product before and after any changes, as well as on the procedures and deadlines for the submission and approval of variations. In October 2017 the WHO Expert Committee on Biological Standardisation developed and published the «Guidelines on procedures and data requirements for changes to approved biotherapeutic products». The WHO recommendations are primarily aimed at resolving the complexities and current problems in the global life cycle management of biotherapeutic products. Guidelines suggest approaches that ensure continued quality, efficacy, and safety of this group of products, as well as continuity in supply and access. The purpose of this paper was to analyse the WHO recommendations on post-approval changes to biotherapeutic products in order to develop harmonised approaches to the assessment of post-approval changes to biological medicinal products in the Russian Federation. The categories of quality changes, supporting data, conditions to be fulfilled, procedures and deadlines set forth in this paper can serve as a basis for further improvement of the national regulatory and methodological framework.